Anumana
David McMullin has more than two decades of experience in corporate development, strategic planning, commercialization, and operations across multiple sectors in the life sciences industry. In addition to serving as a chief business officer of Anumana, he continues in his role of chief strategy officer of nference.
Prior to joining nference and Anumana, Mr. McMullin served as a chief business officer of Aldeyra Therapeutics, a Nasdaq-listed biotechnology company. Before Aldeyra, Mr. McMullin ran U.S. Internal Medicine at Shire plc, a $1.4 billion rare disease, and specialty pharmaceutical company, and was previously the head of Global Commercial Operations at the Shire. Prior to his work at the Shire, he was the vice president of Global Supply Chain Management and Strategy at Novartis. He holds an MBA with high distinction as a Baker Scholar from Harvard University and a bachelor’s degree in Economics from Brigham Young University.
This person is not in any offices
Anumana
1 followers
Anumana is an AI-driven company that develops ECG algorithms enabling early disease diagnosis and intervention.